Safety Study With the Antibody, cG250, and Isotope, 124-Iodine, to Diagnose Patients With Renal Masses.

NCT ID: NCT00199888

Last Updated: 2022-10-10

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE1
• Total Enrollment: 26 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2005-06-30
• Study Completion Date: 2009-05-29

Brief Summary

The purpose of this study is to see if an antibody (cG250) attached to a radioactive substance (Iodine-124) safely detects clear cell renal cancer in patients with kidney tumors scheduled for surgery.

Detailed Description

Antibodies are proteins made by the immune system. They fight things that the body sees as foreign, such as bacteria and viruses. The body can also see cancer cells as foreign. When the body sees a foreign invader, it sends out antibodies that tag the invader. Once this happens, the immune system can work to destroy whatever the antibody has tagged.

Monoclonal antibodies are antibodies that can be made in the lab. They tag a portion of a cancer cell. Early monoclonal antibodies were made from antibodies grown in mice. They caused an antibody response in humans after one dose. Now they are more like human antibodies, and thus, do not produce the same reactions on repeated doses. These are called chimeric antibodies. The antibody we will use in this study is called chimeric G250 (cG250).

Recent research has shown that some antibodies can attach themselves to cancer cells, and that they bind to very few normal cells. This could help cancer treatment in two ways. One is that the body's own immune system might work to destroy tagged cancer cells. The other is that we can attach chemotherapy drugs or radioactive chemicals to the antibodies. These can then deliver treatment when the antibodies attach to the cancer cells.

This study is being done to test the tagging ability of cG250 to cancer cells. After you receive cG250, you will have a scan. The picture the scan produces will show where the antibody has collected inside the body. From this, it is possible to measure how well cG250 can detect kidney cancer. This is NOT a treatment for renal cancer. After your surgery, we will examine the tumor and other tissue to see how much of the antibody has attached to the tumor.

Conditions

Cancer of Kidney; Kidney Cancer; Renal Cancer; Neoplasms, Kidney; Renal Neoplasms; Renal Cell Carcinoma (RCC); Clear Cell Renal Cell Carcinoma

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: DIAGNOSTIC
• Blinding Strategy: NONE

Study Groups

124I-cG250

Patients who were scheduled for surgical resection of renal masses received a single intravenous (IV) dose of 10 mg of 5 milliCurie (mCi) /10 mg 124I-cG250. Patients underwent Positron-Emission Tomography/Computed Tomography (PET/CT) imaging of the whole body on at least 2 occasions: once following injection and once immediately prior to surgical resection. Patients were scheduled for surgical resection of their renal masses on day 8.

Group Type: EXPERIMENTAL

124-Iodine-cG250 (124I-cG250)

Intervention Type: DRUG

Interventions

124-Iodine-cG250 (124I-cG250)

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

1. Presence of a renal mass.

2. Scheduled for surgical resection of renal mass.

3. Expected survival of at least 3 months.

4. Karnofsky performance scale ≥70.

5. The following laboratory results should be within the following limits within the last 4 weeks prior to study day 1:

• Absolute neutrophil count (ANC) ≥ 1.5 x 10E9/L
• Platelet count ≥ 100 x 10E9/L
• Serum bilirubin ≤ 2.0 mg/dL
• Aspartate aminotransferase (AST) ≤ 2.5 x upper limit of normal (ULN)
• Alanine aminotransferase (ALT) ≤ 2.5 x ULN
• Serum creatinine ≤ 2.0 mg/dL

6. Pregnancy Test to be performed on female patients of childbearing potential within 24-48 hours before administration of radioactive material.

7. Recovered from toxicity of any prior therapy.

8. Able and willing to give valid written informed consent.

Exclusion Criteria

1. Intercurrent medical condition that may limit the amount of antibody to be administered.

2. Intercurrent medical condition that renders the patient ineligible for surgery.

3. New York Heart Association Class III/IV cardiac disease.

4. History of autoimmune hepatitis.

5. Chemotherapy, radiotherapy, or immunotherapy within 4 weeks prior to the first cG250 dose.

6. Mental impairment that may compromise the ability to give informed consent and comply with the requirements of the study.

7. Lack of availability for immunological and clinical follow-up assessments.

8. Participation in any other clinical trial involving another investigational agent within 4 weeks prior to enrollment.

9. Women who are pregnant or breastfeeding.

10. Allergy to iodine.

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Memorial Sloan Kettering Cancer Center

OTHER

Sponsor Role: collaborator

Ludwig Institute for Cancer Research

OTHER

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Chaitanya R Divgi, MD

Role: PRINCIPAL_INVESTIGATOR

Memorial Sloan Kettering Cancer Center

Pual Russo, MD

Role: PRINCIPAL_INVESTIGATOR

Memorial Sloan Kettering Cancer Center

Locations

Memorial Sloan-Kettering Cancer Center

New York, New York, United States

Countries

United States

References

Divgi CR, Pandit-Taskar N, Jungbluth AA, Reuter VE, Gonen M, Ruan S, Pierre C, Nagel A, Pryma DA, Humm J, Larson SM, Old LJ, Russo P. Preoperative characterisation of clear-cell renal carcinoma using iodine-124-labelled antibody chimeric G250 (124I-cG250) and PET in patients with renal masses: a phase I trial. Lancet Oncol. 2007 Apr;8(4):304-10. doi: 10.1016/S1470-2045(07)70044-X.

Reference Type: DERIVED

PMID: 17395103 (View on PubMed)

Other Identifiers

MSKCC IRB#: 05-004

Identifier Type: OTHER

Identifier Source: secondary_id

LUD2002-003

Identifier Type: -

Identifier Source: org_study_id